|
'Pathway Search Results'
- Selection criteria for significant gene list :
-
Significant genes are selected with a p value cut-off of 0.1. The resultant list was then sorted in a descending order of fold change value. From the sorted list, the top 100 genes were selected for pathway/network. If the gene list is less than 100, the entire gene list was taken for pathway/network analysis.
|
>>Total hits : 8
, Search term given : Prostate AND Cancer
|
Prostate cancer progression
|
GEO Description : Expression profiling of prostate cancer tumors that are benign, clinically localized, or metastatic and refractory to hormones. Results compared to those obtained from immunoblotting to identify concordant changes in mRNA and protein levels.
Organism : Homo sapiens
GEO-ID : GDS1439
|
|
|
- Compared Group :
- primary Vs benign
|
- Number of Nodes in the Network : 25
- Number of Nodes passing Cut-Off : 100
- PValue Cut-Off : 1.79569653369072e-07
- Fold Change Cut-Off : 2.11
|
|
|
- Compared Group :
- primary Vs metastatic
|
- Number of Nodes in the Network : 32
- Number of Nodes passing Cut-Off : 100
- PValue Cut-Off : 6.33205043953922e-10
- Fold Change Cut-Off : 2.11
|
|
|
- Compared Group :
- benign Vs metastatic
|
- Number of Nodes in the Network : 25
- Number of Nodes passing Cut-Off : 100
- PValue Cut-Off : 1.53812448888679e-10
- Fold Change Cut-Off : 2.0
|
Prostate cancer and mTOR inhibitors
|
GEO Description : Analysis of prostate from transgenic mice expressing AKT (hyperactivated in some prostate cancers) treated with mammalian target of rapamycin (mTOR) inhibitor RAD001, and sacrificed after 12 or 48 hours. mTOR inhibition induced apoptosis and reverted a neoplastic phenotype in AKT-expressing prostate
Organism : Mus musculus
GEO-ID : GDS952
|
|
|
- Compared Group :
- placebo Vs RAD001
|
- Number of Nodes in the Network : 34
- Number of Nodes passing Cut-Off : 100
- PValue Cut-Off : 4.91629634780111e-08
- Fold Change Cut-Off : 2.04
|
|
|
- Compared Group :
- wild type Vs AKT transgenic
|
- Number of Nodes in the Network : 26
- Number of Nodes passing Cut-Off : 100
- PValue Cut-Off : 1.15338813794587e-17
- Fold Change Cut-Off : 2.25
|
|
|
- Compared Group :
- 12 h Vs 48 h
|
- Number of Nodes in the Network : 16
- Number of Nodes passing Cut-Off : 100
- PValue Cut-Off : 0.000201503789867274
- Fold Change Cut-Off : 2.07
|
Arachidonic acid effect on prostate cancer cells
|
GEO Description : Analysis of PC-3 prostate cancer cells incubated with arachidonic acid (AA). AA is an omega-6 fatty acid shown to induce cancer cell proliferation. Results suggest AA plays an important role in stimulation of growth-related genes and proliferation via phosphatidylinositol 3-kinase (PI3K) signaling.
Organism : Homo sapiens
GEO-ID : GDS1736
|
|
|
- Compared Group :
- control Vs arachidonic acid
|
- Number of Nodes in the Network : 43
- Number of Nodes passing Cut-Off : 100
- PValue Cut-Off : 0.000134568414068781
- Fold Change Cut-Off : 2.02
|
Androgen receptor modulator effect: time course (HG-U133A)
|
GEO Description : Analysis of LNCaP cells treated for 6 and 24 hours with RTI-018, an androgen receptor (AR) ligand with a mechanism of action different from that of canonical agonists. Results provide insight into the link between RTI-018 induced AR conformational changes and its ability to regulate gene expression.
Organism : Homo sapiens
GEO-ID : GDS2057
|
|
|
- Compared Group :
- control Vs RTI-018
|
- Number of Nodes in the Network : 8
- Number of Nodes passing Cut-Off : 100
- PValue Cut-Off : 2.02323402476168e-08
- Fold Change Cut-Off : 2.08
|
DISCLAIMER: The interactions, networks, list of genes/molecules or any other information presented here, is HYPOTHETICAL in nature and is based on information collected from public as well as other sources, and is analyzed by certain automated mining and analysis software workflows. Strandlife Science Pvt.Ltd. or the Editors of PathwayWorld offer this information with NO CLAIMS of accuracy and WARRANTIES of any kind, and DO NOT Accept liability or legal responsibility for losses allegedly caused by using this information.
GeneSpring® is a registered trademark of Agilent Technologies. GeneSpring® is developed on AVADIS from Strand Life Sciences
|